01:23:13 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
2cureX är verksamma inom cancerbehandling. Idag tillhandahåller bolaget olika verktyg som används av läkare vid behandlingar för att mäta effekt och resistens hos cancerläkemedel på patientens egna cancerceller. Målet är att förkorta behandlingsperioden samt hitta rätt individuell behandling. Idag innehas störst verksamhet på den europeiska marknaden. Huvudkontoret ligger i Köpenhamn.

Kalender

2023-02-23 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-08-08 Extra Bolagsstämma 2022
2022-05-25 Ordinarie utdelning 2CUREX 0.00 SEK
2022-05-24 Kvartalsrapport 2022-Q1
2022-05-24 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-28 Ordinarie utdelning 2CUREX 0.00 SEK
2021-05-27 Kvartalsrapport 2021-Q1
2021-05-27 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-02 Extra Bolagsstämma 2020
2020-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2020-05-28 Årsstämma 2020
2020-05-28 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2019-05-28 Årsstämma 2019
2019-05-17 Kvartalsrapport 2019-Q1
2019-04-02 Extra Bolagsstämma 2019
2019-03-01 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2018-05-28 Årsstämma 2018
2018-05-18 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017
2022-06-28 08:45:00

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, today announced the signature of a distribution agreement for Israel with Gamidor Diagnostics, a medical diagnostic leader in that country. The Israelian market is of high strategic importance for 2cureX because of its innovation and trendsetting.

2cureX and Gamidor Diagnostics have signed an agreement by which Gamidor Diagnostics becomes the distributor of IndiTreat® products in Israel. Under the terms of the collaboration, Gamidor Diagnostics will promote IndiTreat® to oncology professionals, sign supply agreements with hospitals and manage the sample logistics between the hospitals and the 2cureX labs in Copenhagen

Despite a population of just 9 million people, Israel has a particularly active pharma, biotech and medtech industry, including approximately 1,500 startups in the field. The interaction of these companies with world-class health institutions in a limited space has produced one of the most innovative healthcare hubs in the world. Being present in this market will enhance IndiTreat® visibility, both with local and global stakeholders.

IndiTreat® now present in 16 countries

“Gamidor Diagnostics is a very strong player in the diagnostic field in Israel, with an outstanding product portfolio. We are thrilled to welcome them as a 2cureX partner,” says Fernando Andreu, CEO of 2cureX. “With this agreement, IndiTreat® is present in 16 countries already and we are well on our way to reaching the goal of 20 countries by the end of 2022”.

Adding IndiTreat® to Gamidor´s leading oncology portfolio

“Gamidor Diagnostics has been a leading supplier of cancer diagnostic systems to the Israeli pathology market for over 25 years and is committed to playing a role in eradicating cancer. With our vision to work for a healthier world through reliable medical diagnosis, it is a pleasure to add IndiTreat® to our Diagnostics product offering. We strongly believe it will meet the interest from both patients and doctors in our country”, says Michal London, Senior Vice President and Division Head of Tissue, Research, Women's Health and POC at Gamidor Diagnostics.

Israel is an important and highly dynamic market

“Israel is known for its highly dynamic medical technologies environment, as well as for its focus on healthcare. Hospitals and doctors are of the highest quality, and I am glad that we will now be able to offer mCRC patients in Israel an individualized drug response profile and help improve their treatment”, says Jesper Floyd Kristiansen, VP Global Business Development at 2cureX. “I am looking forward to starting the collaboration with the team from Gamidor Diagnostics“.

The agreement has been signed for an initial term of three years, with automatic renewal for successive terms. Other terms of the agreement have not been disclosed. Sales impact of this agreement is expected to show in 2022.